Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

How to Forecast Pharma Stocks (PFE, RAD, JNJ)

By John Jagerson and Wade Hansen
Pharma companies like PFE, JNJ and RAD are very tricky for fundamental analysts. But principles of relative-strength analysis should still be applied to confirm the fundamental factors.

Trade of the Day: Pfizer (PFE)

By John Jagerson and Wade Hansen
PFE is bouncing off support -- and, as a perennial powerhouse, we expect the stock to move back up toward its recent highs.

4 Cheap Pharma Stocks for Quick Profits

By Profit Scanner
For investors who rely on technical signals, these four cheap pharma stocks are showing signs of moving up in the next few days. Buy these pharma stocks now to net profits.

3 Best-of-Breed Small Caps: Biotech Stocks to Buy

By Jason Jenkins, InvestorPlace Contributor
These three small-cap biotech stocks have a bright future and the ability to create advantages in the market.

Investing in Alzheimer’s Disease Drugs Just Became Complicated

By James Brumley, InvestorPlace Feature Writer
Everything pharmaceutical companies thought they knew about Alzheimer's disease may (or may not) be wrong.

Trade of the Day: Rigel Pharmaceuticals (RIGL)

By Rick Rouse, Editor, Momentum Options
I'm still focusing on bullish trades given that stock market support levels have held.

Valeant Shareholders May Lose in the Salix ‘Win’ (VRX, SLXP, ENDP)

By James Brumley, InvestorPlace Feature Writer
Valeant Pharmaceuticals (VRX) swiped Salix Pharmaceuticals (SLXP) from Endo International (ENDP), but was it really worth it?

Trade of the Day: Merck (MRK)

By Ken Trester
With major U.S. stock indexes returning to bullish trends, today's trade is a call option in "Big Pharma" stock Merck (MRK).

Great Biotech Stocks for Retirement Investors

By Aaron Levitt, InvestorPlace Contributor
Yes, Biotech stocks DO belong in your retirement portfolio. Here are three ways to add them and reap the rewards.

Pfizer, Merck Stock – Same Ol’ Slumping Revenues, Same Mixed Prospects

By Dan Burrows, InvestorPlace Feature Writer
The loss of exclusivity on blockbuster drugs continued to weigh in the top line at both Pfizer and Merck in the most recent quarter.

CLVS: Clovis Oncology Lung Cancer Drug Gets Breakthrough Therapy Designation

By Christopher Freeburn, InvestorPlace Writer
Clovis Oncology says the Food and Drug Administration has granted Breakthrough Therapy status to its new lung cancer drug, sending CLVS shares bouncing.

AZN, PFE: Pfizer Confirms Interest in Buying AstraZeneca

By Christopher Freeburn, InvestorPlace Writer
Pfizer says it has approached AstraZeneca about a possible $100 billion merger deal, sending AZN stock surging in Monday trading.

2 Clear Signs That Biotechs and Pharmaceuticals Have Peaked

By James Brumley, InvestorPlace Feature Writer
Pharmaceuticals and biotechs have been too hot for their own good, fueled by increasingly iffy M&A and an oddly high level of IPO activity.

CYTK: Cytokinetics Stock in Ugly Free Fall on ALS Drug Fail

By Christopher Freeburn, InvestorPlace Writer
Cytokinetics stock plunged 60% after CYTK revealed that its amyotrophic lateral sclerosis drug hadn't met the primary goal of a mid-stage clinical trial.

ABBV: AbbVie Beats Street on Soaring Humira Sales

By Christopher Freeburn, InvestorPlace Writer
Pharmaceutical-maker AbbVie posted first-quarter sales that beat estimates on surging sales of its Humira drug, sending ABBV stock higher.

Grass Pollen Allergy? New Grastek Pill From Merck Hits Shelves Soon

By Christopher Freeburn, InvestorPlace Writer
Merck says the U.S. Food and Drug Administration has approve the release of its Grastek grass pollen allergy drug, which will launch later this month.

Pharmaceuticals Deals: QCOR Gets a Big Premium, Roche Goes Shopping

By Dan Burrows, InvestorPlace Feature Writer
Monday's big pharmaceuticals deals included Mallinckrodt buying Questcor for $5.6B -- a 27% premium to QCOR stock -- and Roche picking up Ranbaxy.

4 Ways Obamacare Will Affect Stocks

By James Brumley, InvestorPlace Feature Writer
Obamacare is here to stay. That's good for some stocks, and horrible for others. Here's a look at the winners and losers.

Purdue’s Pill Success Is Bad News for Zogenix Zohydro, ZGNX Stock

By Christopher Freeburn, InvestorPlace Writer
Purdue Pharma's plans to pursue FDA approval of its back-pain medication could mean the end of a Zogenix drug, sending ZGNX stock plunging.
Load More